Ipsen, Genfits Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
GNFT Stock | USD 4.21 0.06 1.41% |
Slightly above 62% of Genfit's investor base is looking to short. The analysis of the overall investor sentiment regarding Genfit suggests that many traders are alarmed. Genfit's investing sentiment can be driven by a variety of factors including economic data, Genfit's earnings reports, geopolitical events, and overall market trends.
Genfit |
Ipsen SA and Genfit SA announced topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis who have shown inadequate response or intolerance to ursodeoxycholic acid , the current standard therapy. PBC is a chronic disease in which the bile ducts in the liver are slowly destroyed. The trial met its primary composite endpoint, with 51 percent of patients on elafibranor 80mg exhibiting a cholestasis
Read at finance.yahoo.com
Genfit Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Genfit can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genfit Fundamental Analysis
We analyze Genfit's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genfit using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genfit based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Genfit is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Genfit Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genfit stock to make a market-neutral strategy. Peer analysis of Genfit could also be used in its relative valuation, which is a method of valuing Genfit by comparing valuation metrics with similar companies.
Peers
Genfit Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
CSBR | Champions Oncology | 4.87 | ||||
MNOV | MediciNova | 2.99 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
ADAG | Adagene | 1.30 | ||||
RZLT | Rezolute | 1.00 | ||||
FENC | Fennec Pharmaceuticals | 0.83 | ||||
ACRV | Acrivon Therapeutics, | 0.80 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
MOLN | Molecular Partners | 0.17 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
KROS | Keros Therapeutics | 1.38 | ||||
JANX | Janux Therapeutics | 2.54 | ||||
HRMY | Harmony Biosciences | 3.02 | ||||
ELYM | Eliem Therapeutics | 5.88 | ||||
HCWB | HCW Biologics | 6.00 |
Additional Tools for Genfit Stock Analysis
When running Genfit's price analysis, check to measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.